Test your knowledge of this functional gastrointestinal tract disorder by taking this short quiz based on facts from the National Institute of Diabetes and Digestive and Kidney Diseases.
Test your knowledge of this functional gastrointestinal tract disorder by taking this short quiz based on facts from the National Institute of Diabetes and Digestive and Kidney Diseases.
November is Stomach Cancer Awareness Month. Test your knowledge of stomach/gastric cancer by taking our short quiz that is based on facts from the National Institutes of Health’s National Cancer Institute.
November is Stomach Cancer Awareness Month. Test your knowledge of stomach/gastric cancer by taking our short quiz that is based on facts from the National Institutes of Health’s National Cancer Institute.
Test your knowledge of chronic hiccups by taking this short quiz based on facts from the Genetic and Rare Diseases Information Center of the National Institutes of Health.
Test your knowledge of chronic hiccups by taking this short quiz based on facts from the Genetic and Rare Diseases Information Center of the National Institutes of Health.
Primary Raynaud phenomenon would most likely affect which of the following patients?
When a person with primary Raynaud phenomenon is experiencing a Raynaud episode, he or she should seek...
Primary Raynaud phenomenon would most likely affect which of the following patients?
When a person with primary Raynaud phenomenon is experiencing a Raynaud episode, he or she should seek...
Vonoprazan offers an effective alternative treatment to intravenous proton pump inhibitors for prevention of rebleeding among patients with high-risk peptic ulcers, researchers found.
Vonoprazan offers an effective alternative treatment to intravenous proton pump inhibitors for prevention of rebleeding among patients with high-risk peptic ulcers, researchers found.
Results showed that a lower fibrosis stage (F0–1) was associated with a significantly reduced risk of cirrhosis and liver-related outcomes compared to patients with advanced fibrosis (F4).
Results showed that a lower fibrosis stage (F0–1) was associated with a significantly reduced risk of cirrhosis and liver-related outcomes compared to patients with advanced fibrosis (F4).
The U.S. Food and Drug Administration (FDA) on October 4 approved the Cologuard Plus multitarget stool DNA test for adults ages 45 and older who are average risk for colorectal cancer.
The U.S. Food and Drug Administration (FDA) on October 4 approved the Cologuard Plus multitarget stool DNA test for adults ages 45 and older who are average risk for colorectal cancer.